Medical Device Stocks
Recent market-moving SEC filings and news across medical device companies, ranked by Wiseek's 1–10 importance score.
How Wiseek curates this list
Every item here is a high-importance (score ≥ 7) SEC filing or licensed news event for a medical device company, sourced from SEC EDGAR and licensed news wires and ranked by Wiseek's 1–10 importance score. The underlying source is linked from each article. See our methodology and editorial policy.
Related Healthcare industries
Biotech StocksPharmaceutical StocksHealth Tech StocksDiagnostics & Research StocksMedical Instrument StocksHealthcare Facility Stocks
See the full Healthcare sector feed.
Treace Medical Launches SuperBite and Three Other Products, Full Rollout in Q3
HeartSciences Faces Nasdaq Delisting After Equity Shortfall
HeartSciences Faces Nasdaq Delisting After Equity Shortfall
Elutia Faces Nasdaq Delisting After Stock Sinks Below $1.00
Inogen Q2 2026: Revenue Climbs 3%, Adjusted EBITDA Turns Positive, Full-Year Outlook Lifted
Shoulder Innovations Files $300M Shelf and Registers 8.1M Share Resale by Insiders and Major Holders
STERIS Q1 FY2027: Revenue +7.3%, EPS $2.04; New $1B Buyback; $55M-$70M Restructuring Announced
Establishment Labs Q2 Revenue Jumps 32%, Loss Narrows; Refinances Debt with $300M Oaktree Facility
Cytosorbents Q2 2026 Earnings Call: Nears Cash Flow Breakeven, Advances FDA Path for DrugSorb-ATR
Artivion Q2 2026: Revenue Up 11% but Net Loss of $(13.5)M on Endospan Deal Costs and Contingent Consideration Charge
iRhythm to Acquire VitalConnect for $287.5M, Expanding Remote Cardiac Care
Nano-X Locks In $8M Registered Direct Offering at $1.00/Unit with Warrants
Treace Medical Lifts 2026 Revenue Outlook to $204M-$212M
Rapid Micro Q2 Revenue Climbs 11%, Gross Margin Reaches 15%, but Cash Burn Accelerates; Workforce Cuts Announced
Treace Medical Q2 Revenue Dips 4% but Cost Cuts Narrow Loss; Bylaws Tightened
Treace Medical Reports Q2 2026 Revenue of $45.4M, Narrows Loss, and Raises Full-Year Revenue Guidance
Rapid Micro Biosystems Reports Q2 Revenue Growth & Record Gross Margin, Reaffirms 2026 Guidance
Humana Adds Medicare Advantage Coverage for CVRx's Barostim Device
AVITA Medical Raises 2026 Guidance, Sees Cash Flow Breakeven in Q4
QuidelOrtho Reports Q2 Loss, Negative Operating Cash Flow, Confirms Slashed Full-Year Guidance
PacBio Q2 Revenue Misses, New CEO and Restructuring Announced; CFO Adopts 10b5-1 Plan
iRhythm Q2 Revenue Beats, Loss Narrows; $50M Baxter Settlement and $287.5M VitalConnect Acquisition Announced
Outset Medical Reports Q2 Results, Faces Legal & Regulatory Headwinds, Resets Warrant Price
iRhythm to Acquire VitalConnect for $287.5M in Cash and Stock
Shoulder Innovations Q2 Revenue Jumps 56% to $17.2M, Gross Margin Hits 78.3%, but Operating Losses Widen as Spending Surges
SANUWAVE Pulls FY2026 Guidance as CMS Reimbursement Uncertainty and Secondary-Market Pressure Mount
Apyx Medical Q2 Revenue Climbs 22% to $13.9M, Full-Year Guidance Reaffirmed
Fortitude Exec Highlights Record Zcash Pool Migration Ahead of HeartSciences Merger Vote
Sanuwave Misses Q2 Revenue, Swings to Loss, and Withdraws FY2026 Guidance
electroCore Raises 2026 Revenue Growth Outlook to Over 30% After Q2 Beat on Bottom Line
UFP Technologies Q2 Sales Surge 15% to $174M, Margins Expand, but Cash Flow Tightens
CVRx Slashes Full-Year Outlook Despite Q2 Beat, Shares Near 52-Week Low
Inogen Q2 EBITDA Beats, Raises Full-Year Guidance on International Demand
iRhythm Beats Q2 Revenue, Raises Guidance, and Acquires Vital Connect for $287.5M
Beyond Air Regains Nasdaq Compliance, But Faces One-Year Strict Monitoring
Q2 Operating Loss & Control Weaknesses Overshadow YTD Cash Flow
SpyGlass Pharma Q2 Loss Widens to $19.9M; Material Weakness Persists, Cash Runway Through 2028
Profound Medical Q2 Revenue Jumps 62% YTD, Losses Narrow as Commercialization Gains Traction
CytoSorbents Q2 Loss Widens to $0.07/Share, Cash Drops to $5.9M Amid Going Concern
AVITA Medical Q2 Revenue Jumps 18% but Going Concern Warning Persists